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Background: Osteopontin (OPN) can recruit macrophages to the site of inflammation and promote tumorigenesis.
M2 tumor-associated macrophages (M2-TAMs) also play an important role in cancer progression. This study aimed
to clarify the role of OPN and M2-TAMs co-existence in gastric cancer.
Methods: The levels of OPN and M2-TAMs were evaluated by immunohistochemical staining in 170 resected
gastric cancer specimens that were collected from 1998 to 2012. M2-TAMs were identified by staining for an M2
marker, CD204. The prognostic significance and correlation between OPN and CD204 expression were analyzed.
A co-culture system of OPN+-AGS and U937 cells was designed to study the effect of OPN on the skewing of
macrophages toward M2-TAMs for gastric cancer progression in vitro and in vivo.
Results: Patients with high expression (>50%) of OPN or CD204 exhibited poor 5-year overall survival rates (48.61%,
p = 0.0055, and 52.14%, p = 0.0498, respectively). A positive correlation was observed between OPN and CD204
expression and high co-expression of OPN and CD204 demonstrated poor 5-year overall survival rates (48.90%,
p = 0.0131). In the co-culture study, OPN was able to attract U937 cells and skew them toward M2-TAMs through
paracrine action. The M2-TAMs could increase the invasiveness of OPN+-AGS cells and the growth rate of xenograft
of a mixture of co-cultured OPN+-AGS and U937 cells.
Conclusion: OPN can skew macrophages toward M2-TAMs during gastric cancer progression. The co-existence
of OPN and infiltrating M2-TAMs correlates with disease progression and poor survival and thus can serve as a
prognostic marker in gastric cancer.
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Gastric cancer is the second leading cause of cancer
death worldwide with overall 5-year survival rates of less
than 10% [1]. The depth of invasion, extensive lymph
node metastasis, and peritoneal seeding are the main
reasons for high recurrence and mortality [2]. Surgery
remains the only curative therapy for gastric cancer, al-
though some studies reported that adjuvant chemother-
apy and chemoradiation therapy can improve patient
outcomes of resectable gastric cancers [3-5]. More than* Correspondence: ysshan@mail.ncku.edu.tw
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unless otherwise stated.50% of gastric cancer patients who underwent radical re-
section ultimately suffered from local recurrence and
distant metastasis [6]. Therefore, a comprehensive inves-
tigation of the molecular mechanisms underlying the de-
velopment and progression of gastric cancer is critical
for designing better therapeutic strategies for the treat-
ment of gastric cancer.
Epidemiological studies reported that chronic inflam-
mation predisposes cells to malignancy. Additionally,
inhibition of chronic inflammation in patients with pre-
malignant disease could reduce cancer risk and cancer
recurrence [7], suggesting that chronic inflammation can
generate a beneficial microenvironment for tumor pro-
gression and metastatic dissemination. Previous studies
reported that gastric cancer is often accompanied by thes is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 The clinicopathological characteristics of 170
patients with gastric cancer
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Lin et al. BMC Cancer  (2015) 15:128 Page 2 of 10phenomena of gastritis. Gastric adenocarcinoma was also
found to frequently occur in areas of chronic inflammation
[8,9]. Furthermore, gastritis appears to be closely associ-
ated with an increased risk of developing gastric cancer
[10]. Therefore, chronic inflammation is believed to be an
important factor in driving gastric cancer progression.
The tumor microenvironment is a complex milieu that
comprises various inflammatory cells and a network of
signaling molecules. Among the inflammatory cells, the
aberrant infiltration and activation of macrophages is
frequently observed in gastric inflammation and cancer
[11]. The infiltrating macrophages, also termed tumor-
associated macrophages (TAMs), are associated with
poor prognosis in a variety of human cancers and play
important roles in tumor development [12]. In gastric
carcinomas, TAMs infiltration in tumors is associated
with more malignant phenotypes, including tumor
angiogenesis, depth of invasion, nodal status, and clinical
stages [13,14]. Gastric cancer patients with a high level
of TAMs infiltration demonstrated worse outcomes after
surgery than those with a low level of TAMs infiltration
[14]. However, the precise role of TAMs in gastric can-
cer remains unknown.
Osteopontin (OPN) is a secreted matrix glycoprotein
that regulates a number of biological processes. The
overexpression of OPN was observed in various human
cancers and is associated with poor patient outcomes in
a variety of cancers, such as breast cancer [15], lung can-
cer [16], liver cancer [17], gastric cancer [18], colon can-
cer [19], and cervical cancer [20]. In gastric cancer, OPN
has been reported to promote cell growth, invasion, and
metastasis, whereas knockdown of OPN attenuated
these effects in vitro and in vivo [21,22]. We therefore
sought to clarify the correlation between OPN and
TAMs in gastric cancer and its clinical significance.
Methods
Immunohistochemistry
For immunohistochemistry, paraffin embedded samples
of 170 gastric cancer patients who underwent potentially
curative surgery between 1998 and 2012 at the National
Cheng Kung University Hospital (NCKUH), Tainan,
Taiwan were immunostained with an anti-human OPN
antibody (1:200; ab8448; Abcam) and an anti-human
CD204 antibody, a marker of M2 type tumor associated
macrophage (M2-TAM) (1:200; ab53566; Abcam). After
horseradish peroxidase (HRP)-conjugated IgG was added
for 1 hour, the specimens were analyzed by ABC detec-
tion. The degrees of staining intensity were classified
into four grades by comparison with the controls as fol-
lows: 0, negative (same as the negative control); A, weak
staining (<25% of the area); B, moderate staining (≥25%
but <50% of the area); and C, extensive staining (>50%
of the area). Grade C was considered to represent highexpression of the stained protein. This study was ap-
proved by Human Experimental and Ethics Committee
of National Cheng Kung University Hospital (ER-98-
017). The written informed consent for participation in
the study was obtained from participants.
The xenografts samples were immunostained with an
anti-mouse CD31 antibody (1:200; 550274; BD Pharmin-
gen) and an anti-mouse α-smooth muscle actin (α-SMA)
antibody (1:50; ab5694; Abcam). The secondary anti-
bodies, including HRP-conjugated IgG and fluorophore-
conjugated IgG, were selected for imaging.
Co-culture method for studying paracrine effect
Cell lines including monocyte cell line U937, TAM pri-
mary cultured from gastric cancer specimens (TAMcli),
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(OPN+-AGS), and AGS with knockdown of OPN by
short hairpin RNA (OPN-shRNA AGS) were used for
co-culture in this study. A Boyden chamber with a 4-nm
pore size insert was used for co-culture. The U937 or
TAMcli were seeded inside in the insert, and OPN+-AGS
or OPN-shRNA AGS were seeded in the base of the
chamber. After incubation for 72 hours, the condition
medium was collected for future chemoattractant exper-
iments. A monoclonal antibody against OPN, or recom-
binant OPN (rOPN) was also used to observe the
chemoattractant effects of OPN during incubation for
72 hours.
Invasion assay
After the co-culture treatment, 5 × 105 gastric cancer
cells were moved onto 8-μm pore polycarbonate inserts
containing Matrigel (354234; BD Pharmingen) and incu-
bated at 37°C. After 24 hours, the membrane was torn
off slowly, washed in PBS, and stained with Giemsa.
These invasive cells were counted under microscopy and
photographed.
Animal model
Four- to 6-week-old nude mice were obtained from
the National Laboratory Animal Center. The housing
and experimental animal procedures were approved by
the Institutional Animal Care and Use Committee of
NCKU (IACUC 98219). Gastric cancer cells (1 × 106)Figure 1 The existence of OPN and M2-TAMs in gastric cancer specim
(a) The stain intensity is shown from grade 0 to grade C. (b, c) The express
stage (p < 0.05). (d) The OPN score was positively correlated with the CD20were intradermally injected into the nude mice either
alone or mixed with U937 (1 × 106) after a 72-hour
co-culture. The xenografts were observed for 9 weeks
until the mice were sacrificed and were paraffin-embedded
for histological analysis.
Statistical analysis
Univariate and multivariate analysis were used to com-
pare the overall survival and the pathology variables.
Receiver operating characteristic (ROC) curve analysis
was used to determine the value demonstrating the high-
est accuracy in predicting patient outcomes. The prognos-
tic assessment was performed by Kaplan-Meier survival
and Cox Regression analysis to identify significance.
Chi-squared tests were used to analyze the correlation
between OPN/CD204 staining and the clinical patho-
logic features. The relationship between the two vari-
ables of OPN and CD204 was analyzed by a one-way
ANOVA test in GraphPad Prism 5.0 software, and most
of analysis was calculated by SPSS 17.0. Statistical sig-
nificance was set at p < 0.05.
Results
OPN and CD204 were highly expressed in gastric tumor
and correlated with disease progression
The clinicopathological characteristics of the gastric can-
cer patients were described in Table 1. Males constituted
57.06% (97/170) of the patient population, and 46.47%
(79/170) of cases were proximal gastric cancers. Most ofens; the M2-TAMs were stained with a CD204-specific antibody.
ion of OPN and CD204 was significantly correlated with the tumor
4 score (p = 0.0078).
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mean follow-up time was 42.2 months (median follow-
up time was 28.5 months). The different grading of OPN
and CD204 expression in the gastric cancer specimens
were shown in Figure 1a. A total of 53.53% of the cancer
tissue samples demonstrated high expression of both
OPN and CD204. The expression scores of OPN and
CD204 were correlated with the tumor stage, p = 0.0498
and p = 0.0450, respectively (Figure 1b-c). Furthermore,
a positive correlation was observed between OPN andTable 2 The overall survival of 170 gastric cancer patients is a
Univariate analysis (N = 170)
Endpoint status (%)
Survival Death p valu
Gender 0.317
Male 51 (53.7) 44 (46.3)
Female 46 (61.3) 29 (38.7)
Age 0.440
≤50 years 17 (50.0) 17 (50.0)
>50 years 78 (57.4) 58 (43.6)
Tumor Location 0.566
Proximal 46 (58.2) 33 (41.8)
Distal 49 (53.8) 42 (46.2)
Tumor Size (cm) 0.011
≤5 72 (62.6) 43 (37.4)
>5 23 (41.8) 32 (58.2)
Lauren Classification 0.189
Intestinal 45 (61.6) 28 (38.4)
Diffuse 50 (51.5) 47 (48.5)
Tumor Stage 0.000
Early 65 (68.4) 25 (33.3)
Advance 30 (31.6) 50 (66.7)
LN Metastasis 0.000
No 55 (74.3) 19 (25.7)
Yes 40 (41.7) 56 (58.3)
OPN Staining 0.015
≤50% 52 (65.8) 27 (34.2)




OPN vs. CD204 Staining 0.007
≤50% vs. ≤50% 36 (76.6) 11 (23.4)
≤50% vs. >50% 16 (53.3) 14 (46.7)
>50% vs. ≤50% 15 (50.0) 15 (50.0)
>50% vs. >50% 28 (44.4) 35 (55.6)
Statistically significant p values are shown in bold.CD204 expression in gastric cancer, R square (R2) is
0.0630 and p = 0.0078 (Figure 1d). The results indicated
that M2-TAMs infiltration in gastric cancer tissue was
correlated with OPN expression as the disease progressed.
Co-expression of OPN and CD204 was significantly
associated with overall survival
In univariate and multivariate analysis, the tumor size,
tumor stage, lymph node metastasis, OPN expression, and
CD204 expression were significantly associated with overallnalyzed after resection
Multivariate analysis (N = 170)
95% CI
e Mean Lower Upper p value
1.425 1.349 1.501 0.320
64.797 62.673 66.92 0.718
2.494 2.372 2.617 0.991
4.632 4.208 5.507 0.006
2.016 1.875 2.158 0.212
1.491 1.419 1.563 0.000
0.584 0.512 0.656 0.000
2.266 2.125 2.407 0.026
2.304 2.169 2.439 0.049
2.678 2.494 2.861 0.001
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the co-expression of OPN and CD204 was more signifi-
cantly associated with overall survival (p < 0.01) compared
with OPN (p < 0.05) or CD204 (p < 0.05) alone. To confirm
the correlation between the co-expression of OPN and
CD204 and overall survival, ROC curve analysis was used.
We found that the co-expression of OPN and CD204
was highly associated with overall survival. The tumor
size (p = 0.005), tumor stage (p = 0.000), lymph node metas-
tasis (p = 0.000), and co-expression of OPN and CD204
(p = 0.002) were significantly associated with the overall
outcome (Figure 2). The results demonstrated that the
co-existence of OPN and M2-TAMs in gastric cancer
was highly associated with the overall survival of gastric
cancer patients.
High co-expression of OPN and CD204 was a marker of
poor prognosis
Next, we used the chi-square test to evaluate the correl-
ation between OPN/CD204 expression and clinicopatho-
logic characteristics (Table 3). We noted that the tumor
size (p = 0.031), endpoint status (p = 0.015), and CD204
expression (p < 0.001) were significantly correlated with
OPN expression. In the CD204 analysis results, the
tumor stage (p = 0.006), endpoint status (p = 0.034), and
OPN expression (p < 0.001) were also significantly corre-
lated. Interestingly, OPN expression was significantly
correlated with CD204 expression in gastric cancer.
In conjunction with the results shown in Figure 1d,
M2-TAMs infiltration in gastric tumors was highly corre-
lated with OPN expression. Thus, we next analyzedFigure 2 Receiver operating characteristic (ROC) curves for the tumor
OPN and CD204 were used to predict overall gastric cancer survival.
0.540-0.709), tumor stage was 0.710 (95% CI, 0.630-0.789), lymph node met
CD204 was 0.637 (95% CI, 0.554-0.720). These parameters were significantlywhether co-expression of OPN and CD204 correlated
with clinicopathologic characteristics. Similarly, the
tumor stage (p = 0.004) and endpoint status (p = 0.007)
were significantly correlated with the co-expression
of OPN and CD204. The results prove that the co-
expression of OPN and CD204 was associated with the
tumor stage and predicted worse patient outcomes.
Kaplan-Meier survival analysis was used to determine
the overall survival of patients with gastric cancer (Figure 3).
Patients with high expression of OPN demonstrated signifi-
cantly worse overall survival than those with low expres-
sion of OPN (p = 0.0055) and the hazard ratio is 2.039
(95% CI of ratio is 1.220 to 3.406). The 5-year survival rate
of gastric cancer patients with high expression OPN was
48.61%, whereas for patients with low expression OPN the
5-year survival rate was 70.42%. In M2-TAMs analysis, we
found that patients with high expression of CD204 exhib-
ited lower overall survival (p = 0.0498), hazard ratio is 1.653
(95% CI of ratio is 0.995 to 2.745) and a lower 5-year sur-
vival rate (52.14%), compared with low CD204 expressing
patients. Furthermore, the 5-year survival rate of patients
with high co-expression of OPN and CD204 was 48.90%,
whereas that of patients with low co-expression of OPN
and CD204 was 82.10%. These results suggest that high
co-expression of OPN and CD204 was a marker of poor
prognosis in gastric cancer.
A paracrine regulation between OPN and M2-TAMs in
gastric cancer
The dual immunofluorescence results indicated that OPN
and CD204 were co-localized even in high-expression orsize, tumor stage, lymph node metastasis, and co-expression of
The area under the ROC curve for tumor size was 0.624 (95% CI,
astasis was 0.663 (95% CI, 0.581-0.745), and co-expression of OPN and
associated with overall survival (p = 0.005, 0.000, 0.000, and 0.002).
Table 3 OPN and CD204 expression correlated with clinicopathologic characterization
OPN expression (%) CD204 expression (%) OPN vs. CD204 expression (%)
≤50% >50% p value ≤50% >50% p value ≤50% vs.
≤50%





Gender 0.550 0.981 0.795
Male 47 (59.5) 50 (54.9) 45 (57.0) 52 (57.1) 29 (61.7) 17 (56.7) 15 (50.0) 36 (57.1)
Female 32 (40.5) 41 (45.1) 34 (43.0) 39 (42.9) 18 (38.3) 13 (43.3) 15 (50.0) 27 (42.9)
Age 0.758 0.489 0.606
≤50 years 15 (19.0) 19 (20.9) 14 (17.7) 20 (22.0) 7 (14.9) 8 (26.7) 7 (23.3) 12 (19.0)
>50 years 64 (81.0) 72 (79.1) 65 (82.3) 71 (78.0) 40 (85.1) 22 (73.3) 23 (76.7) 51 (81.0)
Tumor Location 0.146 0.480 0.229
Proximal 32 (45.5) 47 (51.6) 39 (49.4) 40 (44.0) 22 (46.8) 9 (30.0) 16 (53.3) 32 (50.8)
Distal 47 (59.5) 44 (48.4) 40 (50.6) 51 (56.0) 25 (53.2) 21 (70.0) 14 (46.7) 31 (49.2)
Tumor Size (cm) 0.031 0.068 0.135
≤5 60 (75.9) 55 (24.1) 59 (74.7) 56 (61.5) 38 (80.9) 20 (66.7) 19 (63.3) 38 (60.3)
>5 19 (60.4) 36 (39.6) 20 (25.3) 35 (38.5) 25 (19.1) 21 (33.3) 14 (36.7) 31 (39.7)
Lauren Classification 0.519 0.738 0.983
Intestinal 36 (45.6) 37 (40.7) 35 (44.3) 38 (41.8) 21 (44.7) 13 (43.3) 12 (40.0) 27 (42.9)
Diffuse 43 (54.4) 54 (59.3) 44 (55.7) 53 (58.2) 26 (55.3) 17 (56.7) 18 (60.0) 36 (51.1)
Tumor Stage 0.379 0.006 0.004
Early 46 (58.2) 44 (48.4) 53 (67.1) 37 (40.7) 34 (72.3) 11 (36.7) 18 (60.0) 27 (42.9)
Advance 33 (41.8) 47 (51.6) 26 (32.9) 54 (59.3) 13 (27.7) 19 (63.3) 12 (40.0) 36 (57.1)
LN Metastasis 0.263 0.082 0.345
No 38 (48.1) 36 (39.6) 40 (50.6) 34 (37.4) 25 (53.2) 12 (40.0) 14 (46.7) 23 (36.5)
Yes 41 (51.9) 55 (60.4) 39 (49.4) 57 (62.6) 22 (46.8) 18 (60.0) 16 (53.3) 40 (63.5)
Endpoint Status 0.015 0.034 0.007
Survival 52 (65.8) 43 (47.3) 51 (64.6) 44 (48.4) 36 (76.6) 16 (53.3) 15 (50.0) 28 (44.4)
Death 27 (34.2) 48 (52.7) 28 (35.4) 47 (51.6) 11 (23.4) 14 (46.7) 15 (50.0) 35 (55.6)
Statistically significant p values are shown in bold; p values were calculated using Fisher’s exact test.
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suggests that OPN was bound to the surface of M2-
TAMs. The IHC staining demonstrated that the macro-
phages were located beside the tumor cells (Figure 4a).
The results implied that paracrine regulation occurs be-
tween OPN and M2-TAMs within gastric cancer. Thus,
we designed a co-culture system to mimic the tumor
microenvironment. To explore the chemoattractant effect
of OPN on M2-TAMs infiltration, U937 (5 × 105) were
cultured in the insert, and OPN+-AGS gastric cancer cells
were grown on the base of a Boyden chamber (Figure 4b).
After incubated for 72 hours, the condition medium was
collected and added into another lower chamber. New in-
sert containing U937 cells was put into the chamber and
then incubated for 72 hours. The number of M2-TAMs in
the lower chamber was significantly increased, compared
with those cells treated with conditioning medium con-
taining a monoclonal OPN antibody (Figure 4c). Further-
more, when rOPN was added to the normal medium,
M2-TAMs were still observed in the base of chamber. Flowcytometry further proved that the M2-TAMs differentiation
was associated with the presence of OPN (Figure 4d).
Taken together, these results suggest that OPN was re-
quired for M2-TAMs infiltration in gastric cancer.
After being co-cultured with OPN+-AGS cells, the
U937 cell demonstrated significantly increased mRNA
levels of CD204 and IL-10, as in TAMcli cells, when
compared with cells co-cultured with OPN-shRNA AGS
cells, stimulated with LPS (to become M1 macrophages
exhibiting increased mRNA levels of IL-1) or treated
with an OPN monoclonal antibody (Figure 5a). This re-
sult proved that OPN was able to recruit monocytes and
skewed them toward a M2-TAMs phenotype in gastric
cancer microenvironments.
M2-TAM promoted gastric cancer progression
After being co-cultured with U937 or TAMcli cells for
3 days, the invasiveness of OPN+-AGS cells was signifi-
cantly increased, but the invasiveness was reduced after
the addition of OPN antibodies (Figure 5b). To assess
Figure 3 The overall survival of gastric cancer patients with variable OPN and CD204 expression was analyzed. Either high OPN
expression (>50% positive staining, p = 0.0055) or high CD204 expression (>50% positive staining, p = 0.0498) in gastric cancer was correlated with
lower overall survival. However, the most significant reduction in overall survival occurred for patients with high co-expression of OPN and CD204
(p = 0.0131). The 5-year survival rate in high OPN expression patients was 48.61%, in low OPN expression was 70.42%, in low CD204 expression
was 66.80%, in high CD204 expression was 52.14%, in high co-expression of OPN and CD204 was 48.9%, and in low co-expression of OPN and
CD204 was 82.10%.
Figure 4 The paracrine effect of OPN skewed macrophages toward M2-TAMs in gastric cancer. (a) Dual immunofluorescence staining
of OPN (green) and CD204 (red) shows co-localization (yellow) in gastric cancer specimens. The immunohistochemistry of CD204 shows that
macrophages did not come in contact with tumor cells. (b) A co-culture method was designed to mimic the tumor microenvironment of gastric
cancer without direct contact between cancer cells and macrophages. (c) The confocal images show that OPN contributed to the recruitment of
U937 cells and skewed the cells toward M2-TAMs after treatment with conditioning medium; this phenomenon could be blocked by an OPN
monoclonal antibody. Recombinant OPN was able to increase CD204 expression on macrophages. (d) The amount of CD204+TAMs was shown
by flow cytometry. The CD204+-TAM phenotype increased dramatically after co-culture with OPN+AGS cells (red, open histogram). Parental cells
(filled histogram), OPN-shRNA AGS cells (orange, open histogram), OPN neutralizing antibody (green, open histogram), or recombinant OPN
(blue, open histogram) were compared. The TAMcli cells isolated from human gastric cancer were used as a positive control.
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Figure 5 The co-expression of OPN and M2-TAMs promotes gastric tumorigenesis. (a) The expression of M1/M2 markers in U937 cells was
analyzed after co-culture treatment by real-time PCR. LPS-treated U937 cells expressed IL-1 as M1 macrophages, and U937 cells alone were used
as a negative control. TAMcli cells isolated from clinical specimens were used as a positive control. After co-culture with OPN+-AGS cells, the
U937 cells differentiated into M2-TAMs expressing high levels of CD204 and IL-10. (b) After 72 hours of co-culture with U937 or TAMcli cells, the
invasiveness of the OPN+-AGS cells increased but that of OPN-shRNA AGS cells did not. The increased cell invasiveness was also blocked by an
OPN monoclonal antibody. (c) The mixture of co-cultured OPN+-AGS and U937 cells inoculated into nude mice showed poor survival compared
with a mixture of co-cultured OPN-shRNA AGS and U937 cells or OPN+-AGS cells alone (p = 0.0498). (d) The neovascularization in the xenografts
was shown by double-staining with anti-CD31 and anti-αSMA antibodies. Less neovascularization with normal vascular structure was found in
xenografts of a mixture of co-cultured OPN-shRNA AGS and U937 cells.
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of co-cultured OPN+-AGS and U937 cells was inoculated
into the back skin of nude mice to observe the growth of
xenografts. Compared with inoculation of OPN+-AGS
cells alone, the xenografts from mixture of co-cultured
OPN+-AGS and U937 cells grew faster and disseminated
to the liver and peritoneal cavity, similar to human gastric
cancer. Those nude mice exhibited poor survival com-
pared with mice inoculated with a mixture of OPN-
shRNA and U937 cells or AGS cells alone (Figure 5c). We
also found that a marked neovascularization occurred in
the xenografts from a mixture of co-cultured OPN+-AGS
and U937 cells, but the neovascularization was reduced in
the tumors generated from a mixture of OPN-shRNA
AGS and U937 cells (Figure 5d). Collectively, these results
proved that OPN could recruit macrophages and skew
them toward M2-TAMs formation and the M2-TAMs fur-
ther promoted gastric cancer progression.
Discussion
Recently, many studies have proven that the infiltrating
inflammatory cells in the tumor microenvironment
could promote cancer progression [23,24]. Chronic in-
flammation is frequently found within gastric tumors,
and M2-TAMs can be observed after staining for M2markers. The correlation between the presence of M2-
TAMs in tumors and poor survival has been demon-
strated in several cancer types [25-27]. However, the
reasons underlying the ability of infiltrating TAMs to
promote cancer progression remain a mystery. We ob-
served that OPN was highly expressed in gastric cancer
specimens and positively correlated with M2-TAMs
infiltration (R2 = 0.7743). More importantly, the co-
existence of OPN and M2-TAMs is significantly corre-
lated with poor prognosis and lower 5-year survival
rates. Although our results are similar to those of previ-
ous reports, we focused on M2-type macrophages
(CD204 staining) rather than total macrophages (CD68
staining) [28,29]. In addition, a previous study demon-
strated that OPN overexpression in TAMs was able to
enhance angiogenesis and growth in melanoma through
autocrine signaling [30] rather than through the interac-
tions with tumor cells. Therefore, this is the first study
to prove the paracrine regulation of M2-TAMs by OPN
to promote gastric cancer progression.
OPN is a secreted glycoprotein that can generate
macrophage accumulation [31] and enhance tumor inva-
sion [32,33]. However, the detailed mechanism remains
unclear. In this study, we used a co-culture system to
demonstrate a paracrine regulation between OPN and
Lin et al. BMC Cancer  (2015) 15:128 Page 9 of 10M2-TAMs in gastric cancer. OPN has the ability to re-
cruit and skew macrophages toward M2-TAMs and thus
promotes gastric cancer progression. OPN has been re-
ported to promote invasion and metastasis of gastric
cancer through HIF-1α upregulation and MMP9 activa-
tion [34]. Moreover, the plasma OPN concentration in
patients with metastatic disease is significantly higher
than that in patients without metastases [35]. In breast
cancer, OPN can promote cancer progression, whereas
knockdown of OPN aborts this effect [36]. Notably,
contradictory results were observed in an OPN knockout
squamous carcinoma mouse model. Primary skin tumors
grew larger and produced more numerous lung metasta-
ses in OPN-deficient mice, compared with their wild-
type counterparts [37]. The controversial findings may
result from the different functions of OPN in normal
tissues and tumors. Our results are consistent with a
previous study which reported that the tumor microenvir-
onment determines the effects of OPN [38]. In the future,
we will further clarify the mechanism underlying the inter-
action between OPN and TAMs in gastric cancer.
Conclusion
Our study clearly demonstrates that clinical parameters,
including tumor size, tumor stage, lymph node metasta-
sis, OPN expression, and TAMs infiltration are associ-
ated with overall survival of gastric cancer patients.
Patients with high co-expression of OPN and CD204 ex-
hibit a lower 5-year survival rate. In vitro and in vivo ex-
periments further verify the interaction between OPN
and TAMs, which can promote gastric cancer progres-
sion. Our novel findings provide a good marker for pre-
dicting the outcomes of patients with gastric cancer.
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